An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease

Primary Immunodeficiency Disease Clinical Trial

Official title:
A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)

Status Completed

Clinical Trial Summary

This study is an extension study for participants with primary immunodeficiency disorders who were previously treated with IGSC, 20% in the TAK-664-3001 study. They must have completed that study or be about to complete it before joining this study. Participants will continue treatment with IGCS, 20% in this study. The main aim of this study is to check for side effects from long-term treatment with IGSC, 20% . This medicine is not yet licensed in Japan, so participants will be treated with IGSC, 20% until it becomes commercially available.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04842643
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 3
Start date	April 27, 2021
Completion date	April 25, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03677557` - Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment	Phase 4
Completed	`NCT02810444` - Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID	Phase 3
Enrolling by invitation	`NCT01150240` - Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland	N/A
Recruiting	`NCT04944979` - Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)	Phase 3
Completed	`NCT02627300` - Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial	Phase 3
Not yet recruiting	`NCT03252548` - Pediatric Primary Immunodeficiency Disease (PID) in China	N/A
Completed	`NCT03961009` - Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients	Phase 3
Not yet recruiting	`NCT06089122` - Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG	Phase 3
Not yet recruiting	`NCT06150833` - Efficacy and Safety and Pharmacokinetics of Boya IVIG	Phase 3